Voyager Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Voyager Therapeutics's estimated annual revenue is currently $15.9M per year.
- Voyager Therapeutics received $75.0M in venture funding in November 2017.
- Voyager Therapeutics's estimated revenue per employee is $99,874
- Voyager Therapeutics's total funding is $135M.
- Voyager Therapeutics's current valuation is $108.2M. (January 2022}
- Voyager Therapeutics has 159 Employees.
- Voyager Therapeutics grew their employee count by -39% last year.
Voyager Therapeutics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Voyager Therapeutics?
Voyager Therapeutics is developing life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. We focus on people living with severe neurological diseases that lack safe and effective treatment options, particularly in the areas of Parkinson's disease, monogenic forms of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, Alzheimer's Disease and other tau-related neurodegenerative diseases, and severe, chronic pain. We are also committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, dosing techniques, as well as process development and production. Our management team and founders represent some of the most esteemed scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference, neuroscience preclinical and clinical development, and manufacturing. We have broad strategic collaborations with Genzyme, a Sanofi company, AbbVie and the University of Massachusetts Medical School (UMMS). We have also entered into license and other agreements with UMMS, the University of California San Francisco and Stanford University to access relevant technology and data. Contact: Voyager Therapeutics 75 Sidney St. Cambridge, MA 02139 firstname.lastname@example.org 857-259-5340keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Voyager Therapeutics News
Voyager Therapeutics, a Cambridge, Mass.-based gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), completed a $60m Series B financing. The round was co-led by new investors Brookside Capital and Partner Fund Manageme ...
Shares of Voyager were up 14 percent on the Nasdaq late Monday morning following the news. Shares of Sanofi were down slightly on the Euronext Paris exchange. Under the restructured relationship, Voyager takes worldwide rights to VY-HTT01, a gene therapy in preclinical, lead-selection developme ...
With its lead gene therapy programs stalled by a series of setbacks, Voyager Therapeutics has been talking for months about refocusing its business on internal technology that finds capsids—the protein shells that envelope a gene therapy and deliver it into a target cell. That strategy is starti ...
On Wednesday, shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) marked $16.77 per share versus a previous $17.11 closing price.
DekaBank Deutsche Girozentrale lifted its stake in Voyager Therapeutics Inc (NASDAQ:VYGR) by 63.6% in the 2nd quarter, according to the ...
On Thursday's Current Session, Voyager Therapeutics, Inc. (NASDAQ:VYGR) closing at $17.00 price level during recent trade its distance from ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Voyager Therapeutics Funding
|2014-02-13||$45.0M||A||Third Rock Ventures||Article|